| Source: |
| Type: |
| Glycolysis is a metabolic pathway that converts glucose into pyruvate, producing a small amount of ATP (energy) in the process. It is a fundamental process for cellular energy production and occurs in the cytoplasm of cells. In normal cells, glycolysis is tightly regulated and is followed by aerobic respiration in the presence of oxygen, which allows for the efficient production of ATP. In cancer cells, however, glycolysis is often upregulated, even in the presence of oxygen. This phenomenon is known as the Warburg Mutations in oncogenes (like MYC) and tumor suppressor genes (like TP53) can alter metabolic pathways, promoting glycolysis and other anabolic processes that support cell growth.effect. Acidosis: The increased production of lactate from glycolysis can lead to an acidic microenvironment, which may promote tumor invasion and suppress immune responses. Glycolysis is a hallmark of malignancy transformation in solid tumor, and LDH is the key enzyme involved in glycolysis. Pathways: -GLUTs, HK2, PFK, PK, PKM2, LDH, LDHA, PI3K/AKT/mTOR, AMPK, HIF-1a, c-MYC, p53, SIRT6, HSP90α, GAPDH, HBT, PPP, Lactate Metabolism, ALDO Natural products targeting glycolytic signaling pathways https://pmc.ncbi.nlm.nih.gov/articles/PMC9631946/ Alkaloids: -Berberine, Worenine, Sinomenine, NK007, Tetrandrine, N-methylhermeanthidine chloride, Dauricine, Oxymatrine, Matrine, Cryptolepine Flavonoids: -Oroxyline A, Apigenin, Kaempferol, Quercetin, Wogonin, Baicalein, Chrysin, Genistein, Cardamonin, Phloretin, Morusin, Bavachinin, 4-O-methylalpinumisofavone, Glabridin, Icaritin, LicA, Naringin, IVT, Proanthocyanidin B2, Scutellarin, Hesperidin, Silibinin, Catechin, EGCG, EGC, Xanthohumol. Non-flavonoid phenolic compounds: Curcumin, Resveratrol, Gossypol, Tannic acid. Terpenoids: -Cantharidin, Dihydroartemisinin, Oleanolic acid, Jolkinolide B, Cynaropicrin, Ursolic Acid, Triptolie, Oridonin, Micheliolide, Betulinic Acid, Beta-escin, Limonin, Bruceine D, Prosapogenin A (PSA), Oleuropein, Dioscin. Quinones: -Thymoquinone, Lapachoi, Tan IIA, Emodine, Rhein, Shikonin, Hypericin Others: -Perillyl alcohol, HCA, Melatonin, Sulforaphane, Vitamin D3, Mycoepoxydiene, Methyl jasmonate, CK, Phsyciosporin, Gliotoxin, Graviola, Ginsenoside, Beta-Carotene. |
| Colorectal cancer is a broader term that encompasses both colon and rectal cancer. |
| 944- | AG, | Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model |
| - | vitro+vivo, | CRC, | NA |
| 2316- | Api, | The interaction between apigenin and PKM2 restrains progression of colorectal cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | HCT8 | - | in-vivo, | CRC, | NA |
| 206- | Api, | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Lung, | H2030 | - | in-vitro, | CRC, | SW480 |
| 2335- | BBR, | Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2708- | BBR, | Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2740- | BetA, | Effects and mechanisms of fatty acid metabolism-mediated glycolysis regulated by betulinic acid-loaded nanoliposomes in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 |
| 990- | CUR, | Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1885- | DCA, | Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 2400- | HCAs, | The Mixture of Ferulic Acid and P-Coumaric Acid Suppresses Colorectal Cancer through lncRNA 495810/PKM2 Mediated Aerobic Glycolysis |
| - | in-vitro, | CRC, | NA | - | in-vivo, | CRC, | NA |
| 2178- | itraC, | Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer |
| - | in-vivo, | CRC, | HCT116 |
| 2390- | KaempF, | Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis |
| - | in-vitro, | CRC, | HCT8 |
| 993- | RES, | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | Nor, | HCEC 1CT |
| 3036- | RosA, | Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3141- | VitC, | High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 |
| 3145- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 4468- | VitC, | SSE, | Selenium modulates cancer cell response to pharmacologic ascorbate |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | CRC, | HCT116 |
| 2369- | VitD3, | Long Non-coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting c-Myc Degradation |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | RKO |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:6 Cells:% prod#:% Target#:129 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid